All News

5 January 2011

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic CancerAntibodies

4 January 2011

Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid TumorsAntibodies

4 January 2011

XOMA and Servier Sign Development and Commercialization Agreement for XOMA 052Antibodies

4 January 2011

AnaptysBio Receives Milestone Payment from Merck for Successful Delivery of Candidate Antibodies for Therapeutic UseAntibodies

30 December 2010

Swedish Orphan Biovitrum returns development rights to Sym001 to SymphogenAntibodies

29 December 2010

Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE Pediatric Ulcerative Colitis IndicationAntibodies

22 December 2010

Biogen Idec and Elan Submit Applications to Update TYSABRI Labeling That May Help Stratify Risk of PML with Anti-JC Virus Antibody StatusAntibodies

21 December 2010

BioInvent Extends Antibody Collaboration with Japanese Pharmaceutical PartnerAntibodies

21 December 2010

AstraZeneca discontinues development of motavizumab for RSV prophylaxis indicationAntibodies

20 December 2010

Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer TrialAntibodies

20 December 2010

Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)Antibodies

20 December 2010

Lpath, Inc. Grants Pfizer Exclusive Option for Worldwide License for iSONEPAntibodies

16 December 2010

FDA begins process to remove breast cancer indication from Avastin labelAntibodies

15 December 2010

Epitomics Signs Antibody Development Agreement With the National Cancer InstituteAntibodies

14 December 2010

UCB Announces Start of Phase III Program With Epratuzumab for Patients With Moderate to Severe Systemic Lupus ErythematosusAntibodies

14 December 2010

Compugen Announces Positive Therapeutic Effect of CGEN-15001 in Animal Model of Rheumatoid ArthritisAntibodies

14 December 2010

Life Science Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of ABT-806 for the Treatment of CancerAntibodies

14 December 2010

Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of CancerAntibodies

14 December 2010

XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate CancerAntibodies

13 December 2010

ImmunoGen, Inc. Announces Clinical Data for T-DM1 Used in Combination with Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast CancerAntibodies

10 December 2010

Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast CancerAntibodies

9 December 2010

PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of ValortimAntibodies

9 December 2010

VELCADE Induction Followed by VELCADE Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma PatientsAntibodies

8 December 2010

Nanobody Candidate Selected by Boehringer Ingelheim for DevelopmentAntibodies

8 December 2010

iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus RoyaltiesAntibodies

7 December 2010

ZEVALIN Data as Preparatory Regimen Presented Prior to Autologous and Allogeneic Stem Cell Transplantation in the Treatment of Non-Hodgkin’s LymphomaAntibodies

7 December 2010

Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma Presented at 52nd American Society of Hematology Annual MeetingAntibodies

7 December 2010

Data from Phase 2 Study of Alder Biopharmaceuticals’ Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung CancerAntibodies

7 December 2010

Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer TherapyAntibodies

7 December 2010

Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Monoclonal Antibody-Based Therapy for Treatment of Systemic Lupus ErythematosusAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPC3-Targeted Immunotherapy Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

PD-1 Agonists Pipeline Review